(Reuters) – China-based biotech firm Beigene Ltd, said on Friday a late-stage study testing its cancer therapy, tislelizumab, in combination with chemotherapy to treat metastatic nasopharyngeal cancer met the main goal. (https://refini.tv/3ypTB6G)
(Reporting by Trisha Roy in Bengaluru; Editing by Ramakrishnan M.)
